Rockwell Medical (NASDAQ:RMTI) Posts Quarterly Earnings Results

Rockwell Medical (NASDAQ:RMTI) issued its earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10), Zacks reports. The firm had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $17.82 million. Rockwell Medical had a negative return on equity of 13.88% and a negative net margin of 7.33%.

Here are the key takeaways from Rockwell Medical’s conference call:

• Second-quarter net sales rose 11% year over year to $17.8 million, driven by new Western U.S. customers, higher purchasing from existing customers, and pricing actions. Management said it remains on track for 2026 sales guidance of $70 million to $75 million.
• Gross margin expanded to 18% from 16% a year ago, while gross profit increased 30% to $3.2 million. The company attributed the improvement to lower manufacturing costs, automation, higher volumes, and operational efficiencies, and reiterated its full-year gross-margin target of 18% to 22%.
• Rockwell generated approximately $2.1 million in operating cash flow during the quarter and ended June with $24.8 million in cash and available-for-sale investments. Management reiterated expectations for positive operating cash flow and adjusted EBITDA of $1 million to $2 million in 2026.
• Expansion in the Western U.S. is gaining traction, with incremental volume carrying margins above the company average and liquid products representing a larger share of the regional mix. New and renewed customer agreements, generally structured for about three years with pricing escalators, are also increasing revenue visibility.
• The company is evaluating a complementary renal-care medical device that could address a sizable market and potentially face limited U.S. competition. Development remains early-stage, with investment funded from the existing balance sheet and no additional capital raise currently planned.

Rockwell Medical Stock Down 5.2%

RMTI traded down $0.41 on Friday, hitting $7.41. The company had a trading volume of 20,822 shares, compared to its average volume of 35,518. The stock has a fifty day moving average price of $6.48 and a 200-day moving average price of $8.23. Rockwell Medical has a 12-month low of $4.89 and a 12-month high of $21.00. The company has a debt-to-equity ratio of 0.23, a quick ratio of 3.43 and a current ratio of 3.74. The stock has a market capitalization of $29.42 million, a price-to-earnings ratio of -5.53 and a beta of 1.60.

Institutional Trading of Rockwell Medical

A number of institutional investors have recently modified their holdings of the company. XTX Topco Ltd grew its position in shares of Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after buying an additional 46,029 shares during the last quarter. Jane Street Group LLC purchased a new stake in Rockwell Medical during the fourth quarter valued at approximately $84,000. Geode Capital Management LLC boosted its stake in Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after purchasing an additional 148,737 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RMTI. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective (up from $2.00) on shares of Rockwell Medical in a research note on Thursday, July 9th. Weiss Ratings raised shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Rockwell Medical has an average rating of “Hold” and a consensus price target of $20.00.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.